期刊文献+

前列地尔联合羟苯磺酸钙治疗慢性肾衰竭的临床观察 被引量:8

Clinical Observation of Alprostadil Combined with Calcium Dobesilate in the Treatment of Chronic Renal Failure
原文传递
导出
摘要 目的:观察前列地尔联合羟苯磺酸钙治疗慢性肾衰竭(CRF)的临床效果。方法:选择在我院肾内科住院的60例CRF患者,随机分为治疗组(30例)和对照组(30例)。对照组仅给予常规治疗,治疗组在常规治疗的基础上加用前列地尔注射液(10μg,静脉滴注,qd)和羟苯磺酸钙胶囊(500mg,口服,tid)治疗。观察2组治疗前后肾功能(血清尿素氮(BUN)、血肌酐(Scr)、血尿酸(UA)、24h尿蛋白定量、肌酐清除率(Ccr))、血液流变学参数(全血低切黏度、全血高切黏度、血浆黏度)及血脂(总胆固醇(T-CHO)、甘油三酯(TG))水平的变化,并观察不良反应。结果:治疗2周和4周后,治疗组BUN、Scr、UA、24h尿蛋白定量显著下降,Ccr显著上升,且显著优于治疗前和对照组同期,差异有统计学意义(P<0.05),且治疗组全血低切黏度、全血高切黏度、血浆黏度和T-CHO、TG较治疗前及对照组同期显著降低,差异有统计学意义(P<0.05)。2组未见明显不良反应发生。结论:CRF患者在常规治疗基础上应用前列地尔联合羟苯磺酸钙治疗安全、有效。 OBJECTIVE: To observe the clinical efficacy of alprostadil combined with calcium dobesilate in the treatment of chronic renal failure (CRF). METHODS: 60 CRF patients in nephrology department of our hospital were collected and randomly divided into treatment group and control group (n----30). On the basis of the conventional treatment, treatment group was additional- ly treated with Alprostadil injection (10 Ixg, intravenous dripping, qd) and calcium dobesilate (500 mg, orally, tid), while only conventional treatment was performed in control group. Renal function index (BUN, Scr, UA, 24 h urinary protein, Ccr), blood rheology parameters (BVL, BVH, PV) and blood lipid (T-CHO, TG) level were observed in 2 groups before and after treatment and adverse drug reaction was also observed. RESULTS: 2 weeks and 4 weeks later, levels of BUN, Scr, UA and 24 h urinary protein quantitative in treatment group were significantly decreased, while Ccr level was increased significantly, and renal function index of treatment group were significantly better than before treatment and corresponding period of control group (P〈0.05) ; BVL, BVH, PV, T-CHO and TG of treatment group were decreased significantly, compared with before treatment and correspond- ing period of control group (P〈0.05). No obvious adverse drug reaction was found in 2 groups. CONCLUSION: Based on conven- tional treatment, combination of alprostadil and calcium dobesilate is a safe and effective treatment for CRF patients.
出处 《中国药房》 CAS CSCD 2012年第36期3438-3440,共3页 China Pharmacy
关键词 慢性肾衰竭 前列地尔 羟苯磺酸钙 肾功能 血液流变学参数 血脂 Chronic renal failure Alprostadil Calcium dobesilate Renal function Blood rheology parameters Blood lipid
  • 相关文献

参考文献6

二级参考文献11

  • 1钟惠菊,郭丽娟.糖尿病视网膜病变者血浆内皮素水平及导明治疗后的变化[J].湖南医科大学学报,1997,22(1):56-58. 被引量:9
  • 2王立,北京医学,1994年,2卷,18页
  • 3Berthet P, Farine JC, Barras JP. Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy[J]. Int J Clin Pract, 1999, 53( 8): 631.
  • 4Jian Luo, Josephine Quan, Joyee Tsai, et al. Nongenetic mouse models of non- insulin- dependent diabetes mellitus[J]. Metabolism, 1998, 47: 663.
  • 5Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature[J]. Am J Physiol Regul Integr Comp Physiol, 2002, 282( 2): R335.
  • 6Lal MA, Brismar H, Eklof AC, et al. Role of oxidative stress in advanced glycation end product- induced mesangial cell activation[J]. Kidney Int, 2002, 61( 6): 2 006.
  • 7Lee HB, Yu MR, Yang Y, et al. Reactive oxygen species- regulated signaling pathways in diabetic nephropathy[J]. J Am Soc Nephrol, 2003, 14( 8 Suppl 3): 241.
  • 8Brunet J, Farine JC, Garay RP, et al. In vitro antioxidant properties of calcium dobesilate[J]. Fund Clin Pharmacol, 1998, 12( 2): 205.
  • 9Brunet J, Farine JC, Garay RP, et al. Angioprotective action of calcium dobesilate against the increased capillary permeability induced by reactive oxygen species in the rat peritoneal cavity[J]. Eur J Pharmacol, 1998, 358( 3): 213.
  • 10Hannaert P, Brunnet J, Farine JC, et al. Antioxidant- angioprotective actions of calcium dobesilate in diabetic rats[J]. Int J Angiol, 1999, 8( 5): 2.

共引文献599

同被引文献77

  • 1唐力.前列地尔注射液治疗慢性肾功能衰竭临床观察[J].山东大学学报(医学版),2014,52(S02):68-68. 被引量:4
  • 2赵琳琳,解汝娟,隋满姝,禹程远,王秦,王德润,姚春影,石芳芳.住院患者慢性肾衰竭的临床特征分析[J].中华临床医师杂志(电子版),2011,5(24):7370-7373. 被引量:9
  • 3赖威,卢实春,赵纪春,严律南,李波,文天夫,王文涛,马玉奎,刘隽,戴军,赵冀,周静,潘传芳,邓承琪,罗燕,彭玉兰,马步云.前列地尔在肝移植中使用的临床意义评价[J].消化外科,2004,3(5):308-312. 被引量:5
  • 4肖正大,韩改玲,李静,张荣花.2型糖尿病肾病患者血清脂联素水平分析[J].山东大学学报(医学版),2006,44(1):69-72. 被引量:14
  • 5Togo S, Chen H, Takahashi T, et al. Prostaglandin E1 im- proves survival rate after 95% hepatectomy in rats[J]. JSurgRes, 2008,146(1) :66.
  • 6Kawano T, Hosokawa N, Maruta T, et al. Reevaluation of protective effects of alprostadil on hepatic function in patients undergoing hepatectomy[J]. Masui, 2005,54 (9) : 982.
  • 7齐新,刘克强.前列腺素E1引起房室传导阻滞1例[J].天津医药,1993,21(9):563.
  • 8Clemmons DR. Metabolic actions of insulin-like growth factor-1 in normal physiology and diabetes [ J ]. Endocrinol Metab Clin North Am, 2012,41 (2) :425 -443.
  • 9Levin-laina N,Iaina A,Raz I. The emerging role of NO and IGF-1 in ear- ly renal hypertrophy in STZ-induced diabetic rats [ J ]. Diabetes Metab Res Rev,2011,27 ( 3 ) :235 - 243.
  • 10Rodtguez-Iturbe B, Garcta Garcia G. The role of tubulointerstitialinflammation in the progression of chronic renal failure [J]. Nephmn Clin Pratt, 2010, 116(2):eSl-e88.

引证文献8

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部